Yeah I'm back to Basalin again.I found this and I'm wondering if this is something that MNKD could be working on.

Al:

"Yet even though the average connects and dynamics of these new basal insulins are better, an increasing number of KOLs are recognizing that a basal patch pump would be the ideal companion to AFREZZA in type 1 and late type 2. And while that maybe obvious for clinical results, the keys to market success of such basal/bolus therapy with AFREZZA and a basal pump will be simplicity and especially competitive economics. These therapies not only be -- must not only be safe and effective, but must be available without much of a premium in cost.

And while competitive pricing may seem a daunting challenge for these advanced products, that objective is within reach for both AFREZZA and a basal patch pump. Indeed, in the process of better control, we'll significantly lower the overall cost of diabetes.

In summary, I believe that in the near term for early-stage type 2 diabetes, patients will -- with the optimum therapy will prove to be AFREZZA or AFREZZA plus metformin. The data from our study MKC-175 should help support this prediction. In type 1 and late type 2, I expect AFREZZA plus an improved basal insulin, and especially a simple basal patch pump, will prove to be the ideal therapy and without the side effects of most of the alternative antiglycemic drugs that are widely used today. "

http://seekingalpha.com/article/575761-mannkind-s-ceo-discusses-q1-2012-results-earnings-call-transcript?all=false&find=patch